PD-L1 antibody

Catalog No. ABIN2664481

The Mouse Monoclonal anti-PD-L1 antibody has been validated for FACS. It is suitable to detect PD-L1 in samples from Human.

Quick Overview for PD-L1 antibody (ABIN2664481)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-L1 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 29E-2A3

Product Details anti-PD-L1 Antibody

Cross-Reactivity: Chlorocebus aethiops (Green monkey) (Cercopithecus aethiops), Chimpanzee, Marmoset, Squirrel Monkey (Saimiri spec.), Green Monkey (Chlorocebus sabaeus)

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: CD274

Background: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Pathways: Cancer Immune Checkpoints